Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which ...
Wall Street Journal on MSN3h
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand?Pharmaceutical companies are typically rewarded for their innovation with years of market exclusivity before cheaper generics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback